Antipsychotic drug treatment in first-episode psychosis should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?

Journal of Clinical Psychopharmacology

Volumn 30, Issue 2, 2010, Pages 176-180

  Derks, Eske M ^a   Fleischhacker, W Wolfgang ^b   Boter, Han ^a,c   Peuskens, Jozef ^d   Kahn, Rene S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Antipsychotic; First episode patients; Prediction; Remission; Schizophrenia; Treatment

Indexed keywords

NEUROLEPTIC AGENT;

ACCURACY; AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952223519     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181d2193c     Document Type: Article

References (27)

1. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008 102: 230-240.
2. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007; 68: 352-360. (Pubitemid 46506798)
3. Leucht S, Shamsi SA, Busch R, et al. Predicting antipsychotic drug response-replication and extension to six weeks in an international olanzapine study. Schizophr Res. 2008 101: 312-319.
4. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003; 60: 1228-1235. (Pubitemid 37494076)
5. Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005; 162: 939-946. (Pubitemid 40676207)
6. Chang YC, Lane HY, Yang KH, et al. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol. 2006; 26: 554-559. (Pubitemid 44772730)
7. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005; 162: 441-449. (Pubitemid 40343909)
8. van. Os J, Drukker M, Campo J, et al. Validation of remission criteria for schizophrenia. Am J Psychiatry. 2006 163: 2000-2002.
9. Beitinger R, Lin J, Kissling W, et al. Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry. 2008 32: 1643-1651.
10. De Hert M, van Winkel R, Wampers M, et al. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schkophr Res. 2007; 92: 68-73. (Pubitemid 46561226)
11. Emsley R, Oosthuizen P, Koen L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol. 2008 23: 325-331.
12. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007; 89: 129-139. (Pubitemid 44881311)
13. Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006; 26: 571-578. (Pubitemid 44772733)
14. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone-analysis of long-term efficacy. J Psychopharmacol. 2005; 19: 15-21. (Pubitemid 41392293)
15. Lasser RA, Bossie CA, Gharabawi GM, et al. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res. 2005 77: 215-227.
16. Leucht S, Beitinger R, Kissling W. On the concept of remission in schizophrenia. Psychopharmacology (Berl). 2007 194: 453-461.
17. Peuskens J, Kaufman L, Van Vleymen B. Analysis of resolution criteria in patients with, schizophrenia treated with olanzapine for an acute psychotic episode. Schizophr Res. 2007; 95: 169-173. (Pubitemid 47315739)
18. Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005 78: 147-156.
19. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform, disorder: an open randomised clinical trial. Lancet. 2008; 371: 1085-1097. (Pubitemid 351418005)
20. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICID-10. J Clin Psychiatry. 1998; 59(suppl 20): 22-33. (Pubitemid 29001829)
21. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276. (Pubitemid 18039085)
22. Guy W. Clinical Global Impressions (CGI) Scale. In: Rush A. Jr, Pincus H, First M, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 100-102.
23. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial, BMJ. 1996; 312: 345-349. (Pubitemid 26050038)
24. Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand. 1993; 87: 244-252. (Pubitemid 23107274)
25. Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsychoties in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009 115: 97-103.
26. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 164: 1050-1060.
27. Gaebel W, Riesbeck M, Wolwer W, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German. Research Network on Schizophrenia. J Clin Psychiatry. 2007; 68: 1763-1774. (Pubitemid 350247506)